A Canadian company could soon be exporting medical cannabis to Europe.
Manitoba-based Delta 9 Cannabis Inc., announced today that it signed a non-binding letter of intent with CanPharma GMBH and Global Group Kalapa SL to ship its medical cannabis to Germany.
Kalapa is based in Barcelona, Spain, and owns several subsidiary companies. It is a joint venture partner with CanPharma, a Berlin-based firm, that is attempting to acquire a cannabis import license for its operations in Germany.
Under the agreement, Delta 9 has agreed to a minimum of 40 kilograms of cannabis a month (480 kilos per year) and an additional amount of cannabis extracts to CanPharma for sale to medical cannabis patients in Germany.
“We’ve successfully bid for a retail license in Manitoba, we’ve established ourselves in Alberta, we’ve acquired national distribution agreements, and now our focus is on establishing the Delta 9 brand abroad, beginning in Europe,” said Delta 9 CEO John Arbuthnot, in a release.
“We feel very fortunate to be working with a pioneer in cannabinoid treatment in the European Union, and very much look forward to expanding our business together.”